Nuwellis, Inc. Announces Adjournment of Annual Meeting of Stockholders Due to Lack of Quorum
May 17, 2022 16:25 ET
|
Nuwellis, Inc.
MINNEAPOLIS, May 17, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ: NUWE), today announced that the Company’s 2022 Annual Meeting of Stockholders, on May 17, 2022 at 2:00 p.m., was convened and...
Nuwellis, Inc. Announces First Quarter 2022 Financial Results
May 10, 2022 08:00 ET
|
Nuwellis, Inc.
MINNEAPOLIS, May 10, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) announced today its results for the first quarter ended March 31, 2022, which included the following highlights: ...
Nuwellis Announces Presentation of Aquadex®-Related Abstracts at the 2022 Pediatric Academic Societies Meeting
May 09, 2022 13:11 ET
|
Nuwellis, Inc.
MINNEAPOLIS, May 09, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) today announced the presentation of three Aquadex-related abstracts at the annual Pediatric Academic Societies (PAS)...
Nuwellis, Inc. To Announce First Quarter 2022 Financial Results on May 10, 2022
April 12, 2022 08:00 ET
|
Nuwellis, Inc.
MINNEAPOLIS, April 12, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ: NUWE) announced today that its first quarter 2022 financial results will be released on Tuesday, May 10, 2022. The company...
Nuwellis Announces IRB Approval to Begin Its REVERSE-HF Clinical Study
March 15, 2022 07:00 ET
|
Nuwellis, Inc.
MINNEAPOLIS, March 15, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) today announced it has received independent Institutional Review Board (IRB) approval for the trial protocol of the...
Nuwellis, Inc. Announces Fourth Quarter and Full Year 2021 Financial Results
March 01, 2022 08:00 ET
|
Nuwellis, Inc.
MINNEAPOLIS, March 01, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) announced today its results for the fourth quarter and full year ended December 31, 2021, which included the following...
Nuwellis, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
February 22, 2022 17:15 ET
|
Nuwellis, Inc.
MINNEAPOLIS, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ: NUWE), today announced that, effective February 22, 2022, the independent directors approved equity awards under Nuwellis’ 2021...
Nuwellis Initiates REVERSE-HF Study to Evaluate Ultrafiltration for Heart Failure Patients with Fluid Overload
February 17, 2022 08:00 ET
|
Nuwellis, Inc.
MINNEAPOLIS, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) today announced the company will evaluate the clinical outcomes and economic value of its Aquadex® therapy in comparison...
Nuwellis, Inc. to Announce Fourth Quarter 2021 Financial Results on March 1, 2022
February 01, 2022 08:00 ET
|
Nuwellis, Inc.
MINNEAPOLIS, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ: NUWE) announced today that its fourth quarter 2022 financial results will be released on Tuesday, March 1, 2022. The company...
New Category III CPT Code for the Nuwellis Aquadex Ultrafiltration System is Now in Effect
January 25, 2022 08:00 ET
|
Nuwellis, Inc.
EDEN PRAIRIE, Minn., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) today announced that the new and dedicated Category III Current Procedural Terminology (CPT®) code, 0692T for...